DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
Your eGFR determines which GLP-1 is FDA-indicated and safest. Ozempic received the first formal kidney indication in January 2025. Enter your eGFR for stage-specific guidance.
January 2025: First FDA-approved GLP-1 for CKD risk reduction
Ozempic 1.0mg approval for kidney disease progression + cardiovascular death reduction in T2D with CKD, based on the FLOW trial. 24% relative risk reduction in major kidney + CV events. This transformed CKD treatment — now a chronic-care class effect.
Enter your eGFR
eGFR from your most recent kidney panel (BMP/CMP) labs. Most labs report it alongside creatinine. Albuminuria = elevated urinary albumin from a urinalysis test.
Mildly reduced filtration. GLP-1 use unchanged from normal — no renal dosing adjustment. FLOW trial data supports renoprotection at this stage.
FDA evidence: FLOW trial: semaglutide reduced major kidney + CV events in CKD patients including G2 stage.
FDA-indicated for CKD risk reduction in T2D. Strongest renoprotective evidence.
Dual GIP/GLP-1 mechanism, similar renal safety to semaglutide.
Same molecule as Ozempic. Used for weight-loss path if T2D not present.
Ozempic 1.0mg received FDA approval in January 2025 for reducing kidney disease progression and cardiovascular death in adults with T2D and CKD, based on the FLOW trial. It's the first GLP-1 with formal CKD outcomes indication.
eGFR appears on standard kidney panel (BMP/CMP) labs alongside creatinine. Most labs report it automatically. Normal is ≥90; CKD stages are defined by eGFR ranges. Annual testing is standard for adults 40+.
The FLOW trial enrolled T2D patients with CKD. Use in non-diabetic CKD is off-label, though emerging evidence (FLOW-NDx ongoing) suggests benefit may extend. Most insurance approvals require T2D diagnosis.
No formal cutoff in product labeling, but practical use: G4 (eGFR 15-29) is the threshold where most nephrologists pause new GLP-1 initiation. G5 / dialysis is generally not appropriate for new starts. Ongoing patients may continue under specialist supervision.
GLP-1s are renoprotective long-term. Short-term risk: GI side effects (vomiting, diarrhea) can cause dehydration → acute kidney injury, especially in G3+ patients. Aggressive hydration during titration is critical.
CKD staging based on KDIGO 2024 guidelines. Always coordinate GLP-1 initiation with a nephrologist if your eGFR is below 45 (G3a or worse). Dehydration from GI side effects can cause acute kidney worsening — monitor and hydrate aggressively during titration.
Ozempic review →·GLP-1 by liver fibrosis stage·Our methodology